TRESTLE BIOTHERAPEUTICS
Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease. The company's services allow healthcare providers to reduce their reliance on dialysis while also enhancing the disease status of renal patients through the combination of stem cell biology and bio-fabrication. Trestle Biotherapeutics was founded in 2020 by Alice Chen and Ben Shepherd and is based in San Diego, California, United States.
TRESTLE BIOTHERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Life Science Medical Medical Device
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.trestlebio.com
Total Employee:
1+
Status:
Active
Total Funding:
1000 K USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network SSL By Default Global Site Tag
Similar Organizations
Ajax Therapeutics
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Apros Therapeutics
Apros Therapeutics is a biotechnology firm that develops new treatments and medicines for cancer and infectious disease.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
Bioscience Equity Partners
Bioscience Equity Partners focus exclusively on compelling Med Tech and Biosciences investment themes and ventures.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Zura Bio
Zura Bio is a clinical-stage biotechnology company that develops medicines for immune system disorders.
Current Advisors List
Founder
Investors List
KidneyX Innovation Accelerator
KidneyX Innovation Accelerator investment in Grant - Trestle Biotherapeutics
Acequia Capital (AceCap)
Acequia Capital (AceCap) investment in Seed Round - Trestle Biotherapeutics
Asymmetry Ventures
Asymmetry Ventures investment in Seed Round - Trestle Biotherapeutics
Y Combinator
Y Combinator investment in Seed Round - Trestle Biotherapeutics
Sahin Boydas
Sahin Boydas investment in Seed Round - Trestle Biotherapeutics
FAST — by GETTYLAB
FAST — by GETTYLAB investment in Pre Seed Round - Trestle Biotherapeutics
More informations about "Trestle Biotherapeutics"
Trestle Biotherapeutics - Crunchbase Company Profile …
Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease. The company's …See details»
Trestle Bio Announces Research Collaboration with Humacyte
Mar 6, 2025 Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered tissues for patients living with end stage renal disease. Once implanted, these …See details»
Trestle Biotherapeutics - LinkedIn
Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease.See details»
Trestle Biotherapeutics - Y Combinator
Entrepreneur with 20+ years research experience in the fields of developmental biology, stem cell biology, and tissue engineering. Founded Trestle Biotherapeutics to develop a functional therapeutic tissue for patients suffering …See details»
Trestle Biotherapeutics
Feb 18, 2022 SAN DIEGO [June 12, 2023] – Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial …See details»
Trestle Biotherapeutics - VentureRadar
"Trestle Biotherapeutics is developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease.See details»
Trestle Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Explore Trestle Biotherapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Harvard University licenses kidney engineering …
Feb 22, 2022 By Benjamin Boettner (BOSTON/CAMBRIDGE, Mass.) — A newly launched startup is building upon innovations developed over several years at the Wyss Institute for Biologically Inspired Engineering at Harvard University, …See details»
Trestle Biotherapeutics Announces Formation of Advisory Board
Feb 23, 2022 Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs. Learn …See details»
Trestle Bio Announces Research Collaboration with Humacyte
Mar 6, 2025 Trestle Bio Contact: Ben Shepherd +1-619-300-6866 Information Email: [email protected] Contacts Trestle Bio Contact: Ben Shepherd +1-619-300-6866 …See details»
Trestle Biotherapeutics Licenses Innovations from Harvard …
Feb 10, 2022 Trestle Biotherapeutics, a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University. Under the agreement, …See details»
Trestle Biotherapeutics Wins Prestigious KidneyX Prize
Jun 12, 2023 San Diego-based Trestle Bio named one of KidneyX Artificial Kidney Prize Phase 2 winners. SAN DIEGO [June 12, 2023] – Trestle Biotherapeutics today received a $1 million …See details»
Trestle Biotherapeutics - PitchBook
Trestle Biotherapeutics General Information Description. Operator of a biotechnology firm intended to advance biology for kidney diseases. The company's services offer the …See details»
Trestle Biotherapeutics Wins Prestigious KidneyX Prize
Jun 12, 2023 SAN DIEGO--(BUSINESS WIRE)-- Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial …See details»
Trestle Biotherapeutics Licenses Innovations from Harvard
Feb 8, 2022 Trestle Biotherapeutics, Inc. is a pre-clinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, …See details»
Trestle named as one of CONNECT San Diego’s
SAN DIEGO [April 5, 2022] – Trestle Biotherapeutics announced today that is has been selected as a “Cool Company” by Connect San Diego, an organization that helps promote San Diego’s …See details»
Trestle Biotherapeutics Announces License Agreement with …
Feb 15, 2022 Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs. Learn …See details»
Trestle Bio Announces Research Collaboration with Humacyte
Mar 6, 2025 Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc., a commercial-stage biotechnology platform company developing universally …See details»
Trestle Biotherapeutics Joins the Wellcome Leap HOPE Program
May 25, 2023 San Diego-based Trestle Bio funded by Wellcome Leap to accelerate development of bioengineered kidney tissue. SAN DIEGO [May 25, 2023] – Trestle …See details»
Ben Shepherd, PhD | Trestle Biotherapeutics
Co-Founder and Chief Executive Officer. Ben is a vascular biologist, tissue engineer and regenerative medicine scientist by training. He has spent the past 10+ years in industry …See details»